Director Laura Shawver Sells 50,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

On January 6th, 2025, Laura Shawver, the Director of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), sold 50,000 shares of the company’s stock. The shares were sold at an average price of $11.10 each, resulting in a total transaction worth $555,000. Following this sale, Shawver now holds 210,346 shares, valued at approximately $2,334,840.60. This sale marks a 19.21% reduction in her ownership of ARS Pharmaceuticals’ equity.

This transaction was formally reported in a filing with the Securities and Exchange Commission (SEC), accessible for those interested in more details.

Recent Transactions by Laura Shawver

In addition to the recent sale, Laura Shawver executed several other trades in December. On December 2nd, she sold 97,244 shares at an average price of $13.56, which totaled about $1,318,628.64. Just two days later, on December 4th, she sold another 14,772 shares at an average price of $13.75, netting a total of $203,115.00.

ARS Pharmaceuticals Stock Performance

As of Thursday, shares of SPRY opened at $11.43. The stock has a 50-day moving average of $13.18 and a 200-day moving average of $12.67. Over the past year, ARS Pharmaceuticals has seen its stock price reach a low of $5.68 and a high of $18.51. Currently, the company has a market capitalization of approximately $1.11 billion, a price-to-earnings ratio of -22.41, and a beta of 0.96, indicating the stock's volatility relative to the market.

Analyst Ratings

Various financial analysts recently provided updates on ARS Pharmaceuticals stock. For example, Leerink Partners raised their price target from $21.00 to $25.00 while giving the stock an “outperform” rating in a report on September 20th. Another firm, Cantor Fitzgerald, reaffirmed an “overweight” rating and set a price target of $30.00 on October 8th. Overall, four analysts have a buy rating on the stock, with two analysts giving it a strong buy designation. According to MarketBeat, the average rating for ARS Pharmaceuticals is “Buy,” with a consensus price target of $24.00.

Institutional Investment Activity

In recent months, several institutional investors have adjusted their holdings in ARS Pharmaceuticals. For instance, First Turn Management LLC established a new position in the stock valued at roughly $8,603,000 in the third quarter. Moreover, Jacobs Levy Equity Management Inc. increased its stake by 78.9%, acquiring an additional 288,021 shares for a total of 653,048 shares worth approximately $9,469,000. Other firms, including Miura Global Management LLC and Wexford Capital LP, added new positions in the company during the same period. As it stands, approximately 68.16% of the company’s shares are owned by hedge funds and other institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for severe allergic reactions. Notably, the company is working on neffy, which is a needle-free, low-dose intranasal epinephrine nasal spray designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Their products aim to serve healthcare professionals, patients, and caregivers.

Stocks, Investment, Pharmaceuticals